Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

  • Moreno-Martinez, Laura
  • Gaja-Capdevila, Núria
  • Mosqueira-Martín, Laura
  • Herrando-Grabulosa, Mireia
  • Rodriguez-Gomez, Laura
  • Gonzalez-Imaz, Klaudia
  • Calvo, Ana C.
  • Sagartzazu-Aizpurua, Maialen
  • Moreno-García, Leticia
  • Fuentes, Jose Manuel
  • Acevedo-Arozena, Abraham
  • Aizpurua, Jesús María
  • Miranda, José Ignacio
  • López de Munain, Adolfo
  • Vallejo-Illarramendi, Ainara
  • Navarro, Xavier
  • Osta, Rosario
  • Gil-Bea, Francisco Javier
Background and Purpose Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca2+, as a therapeutic target. Experimental Approach A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the superoxide dismutase 1 (SOD1)G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy, including electrophysiology, histopathology, neuromuscular function and survival. Key Results Among the novel FKBP12 ligands, MP‐010 was chosen for its central nervous system availability and favourable in vitro pharmaco‐toxicological profile. Chronic administration of MP‐010 to SOD1G93A mice produced preservation of motor nerve conduction, with the 61‐mg·kg−1 dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates and significant preservation of motor neurones in the spinal cord of treated mice. Notably, MP‐010 treatment significantly extended lifespan by an average of 10 days compared to vehicle. Conclusions and Implications FKBP12 ligands, particularly MP‐010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A collection of three integration-free iPSCs derived from old male and female healthy subjects

  • Rodríguez-Traver, Eva
  • Díaz-Guerra, Eva
  • Rodríguez, César
  • Arenas, Fabián|||0000-0002-4329-8834
  • Orera, Maria|||0000-0003-0079-2055
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Moratalla, Rosario
  • Vicario, Carlos|||0000-0002-7060-0250
Here, we present the characterization of three iPSC lines derived from dermal fibroblasts of old healthy subjects. Fibroblasts were reprogrammed using Sendai viral vectors encoding OCT4, SOX2, KLF4 and c-MYC. The iPSCs expressed endogenous pluripotency markers, could generate the three germ layers (ectoderm, mesoderm and endoderm), maintained a stable karyotype, and were free from Sendai vectors and reprogramming factors. These integration-free iPSCs can serve for establishing control cell cultures in studies searching for phenotypes and mechanisms that could potentially be dysregulated in degenerative diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A collection of integration-free iPSCs derived from Parkinson's disease patients carrying mutations in the GBA1 gene

  • Rodríguez-Traver, Eva
  • Díaz-Guerra, Eva
  • Rodríguez, César
  • Fernández, Pablo
  • Arenas, Fabián|||0000-0002-4329-8834
  • Araúzo-Bravo, Marcos
  • Orera, Maria|||0000-0003-0079-2055
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Moratalla, Rosario
  • Vicario, Carlos|||0000-0002-7060-0250
Mutations in the GBA1 gene, which encodes the lysosomal enzyme Glucocerebrosidase1 are major risk factors for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We have generated induced pluripotent stem cells (iPSCs) from fibroblasts of four PD patients carrying the N370S/wt or the L444P/wt heterozygous mutations in GBA1. The iPSCs presented a normal morphology, expressed endogenous pluripotency markers and could be differentiated into endodermal, mesodermal and ectodermal cells. These iPSCs were free from Sendai viral vectors and reprogramming factors, had a normal karyotype and maintained the original GBA1 genotype.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Generation of an integration-free iPSC line, ICCSICi005-A, derived from a Parkinson's disease patient carrying the L444P mutation in the GBA1 gene

  • Rodríguez-Traver, E.
  • Rodríguez, C.
  • Díaz-Guerra, Eva
  • Arenas, Fabián|||0000-0002-4329-8834
  • Araúzo-Bravo, Marcos
  • Orera, Maria|||0000-0003-0079-2055
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Moratalla, R.
  • Vicario, Carlos|||0000-0002-7060-0250
The L444P mutation in the GBA1 gene which encodes β-glucocerebrosidase-1, is a major risk factor for developing Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We report the generation and characterization of an induced pluripotent stem cell (iPSC) line derived from a female PD patient carrying the L444P/wt mutation. The iPSC line presented a normal morphology, expressed endogenous pluripotency markers, could be differentiated into endodermal, mesodermal and ectodermal cells, was free from Sendai vectors and reprogramming factors, had a normal karyotype and maintained the original GBA1 genotype. Thus, this iPSC line can serve to establish cellular models of PD.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

  • Moreno-Martínez, Laura
  • Gaja-Capdevila, Núria
  • Mosqueira-Martín, Laura
  • Herrando-Grabulosa, Mireia
  • Rodríguez-Gómez, Laura
  • González-Imaz, Klaudia
  • Calvo, Ana C.
  • Sagartzazu-Aizpurua, Maialen
  • Moreno-García, Leticia
  • Fuentes, José Manuel
  • Acevedo-Arozena, Abraham
  • Aizpurua, Jesús M.
  • Miranda, José Ignacio
  • López de Munain, Adolfo
  • Vallejo-Illarramendi, Ainara
  • Navarro, Xavier
  • Osta, Rosario
  • Gil Bea, Francisco Javier
Background and Purpose: Amyotrophic lateral sclerosis (ALS) is a devastating neu-rodegenerative disease with limited treatment options. ALS pathogenesis involvesintricate processes within motor neurons, characterized by dysregulated Ca 2+ influxand buffering in early ALS-affected motor neurones. This study proposes the modu-lation of ryanodine receptors (RyRs), key mediators of intracellular Ca 2+, as a thera-peutic target.Experimental Approach: A novel class of novel FKBP12 ligands that show activityas cytosolic calcium modulators through stabilizing RyR channel activity, weretested in the superoxide dismutase 1 (SOD1) G93A mouse model of ALS. Differentoutcomes were used to assess treatment efficacy, including electrophysiology, his-topathology, neuromuscular function and survival.Key Results: Among the novel FKBP12 ligands, MP-010 was chosen for its centralnervous system availability and favourable in vitro pharmaco-toxicological profile.Chronic administration of MP-010 to SOD1 G93A mice produced preservation ofmotor nerve conduction, with the 61-mg kg 1 dose significantly delaying the onsetof motor impairment. This was accompanied by improved motor coordination,increased innervated endplates and significant preservation of motor neurones inthe spinal cord of treated mice. Notably, MP-010 treatment significantly extendedlifespan by an average of 10 days compared to vehicle.Conclusions and Implications: FKBP12 ligands, particularly MP-010, exhibit prom-ising neuroprotective effects in ALS, highlighting their potential as novel therapeuticagents. Further investigations into the molecular mechanisms and clinical translat-ability of these compounds are needed for their application in ALS treatment., This work was funded by project CIBER-CALSPI2020/08-1, Grants CB06/05/1105 and CB06/05/0041 from the Instituto de Salud Carlos III of Spain, Grants PID2022-140354OB-I00 and PID2020-119780RB-100 from the Agencia Estatal de Investigación, co-funded by European Union (NextGenerationEU, Recovery, Transformation and Resilience Plan), and Grant IT1732-22 from the Basque Government - Eusko Jaurlaritza. F. J. G.-B. was funded byFundacion Roche Stop Fuga de Cerebros programme (BIO19/ROCHE/017/BD) and received support from the IKERBASQUE, Basque Foundation for Science (IKERBASQUE/PP/2022/003). L. M.-M. holds a PhD fellowship from the Euskal Herriko Univertsitatea (UPV/EHU) (PIF19/184). Open access funding provided by Universidad Pública de Navarra.